JPRN-jRCTs051190011招募中2 期
Selecting the best donor among HLA-haploidentical related donors for allogeneic hematopoietic stem cell transplantation using post-transplantation cyclophosphamide for hematological malignancies - Donor Selection Haplo
akamae Hirohisa0 个研究点目标入组 80 人开始时间: 2019年4月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 < 70age old（—）
- 性别
- All
入选标准
- •Among patients with hematological malignancy (indicated in the selection criteria) who are clinically adopted to allo-HSCT because they cannot expect to be cured or long-term survival by any other therapy, patients who do not have or not available HLA serological identical related donors and have HLA-haploidentical donors.
- •1) Age >= 16 and <70 years old
- •2) ECOG PS 0 or 1
- •3) Normal function of major organs
- •4) Informed consent has been acquired
- •5) Major Indication
- •1. Refractory to 1st induction therapy
- •2. Relapse after chemotherapy
- •3. Unfavorable chromosome abnormality including del(5q)/-5, -7/del(7q), abn 3q, 9q, 11q, 20q, 21q, 17q, t(6;9), t(9;22) or complex karyotype
- •4. Normal karyotype and FLT3-ITD mutation
- •5. Intermediate/poor group by JALSG score
- •6. AML with MRC
- •7. History of relapse after allo-HSCT
- •8. CR1 with standard risk or high risk
- •1. Refractory to 1st induction therapy, MRD positive or unevaluable
- •2. Relapse after chemotherapy
- •3. Any of the following poor prognostic factors
- •i) t(9;22) or t(4;11)
- •ii) >= 35 years of age at diagnosis
- •iii) WBC count of more than 30,000/uL for B-ALL, or more than 100,000/uL for T-ALL at diagnosis
- •4. History of relapse after allo-HSCT
- •5.History of relapse after CAR-T therapy
- •(c) Acute leukemias of ambiguous lineage
- •1. Refractory to the first induction therapy
- •2. Relapse after chemotherapy
- •3. Unfavorable chromosome abnormality
- •4. History of relapse after allo-HSCT
- •1. EB-1 or 2
- •2. IPSS intermediate-2 or high
- •3. Transfusion dependent
- •4. History of relapse after allo-HSCT
- •1. AP or BC: refractory to multiple TKIs
- •2. CP beyond 1st CP or AP
- •3. History of relapse after allo-HSCT
- •(f) ATLL, ML
- •Acute or lymphoma type in the PR or better
- •Malignant lymphoma which is classified in the WHO classification (revised 4th edition) which relapse after auto-HSCT or CAR-T therapy due to no sensitivity to chemotherapy or poorly controlled disease with conventional chemotherapy
- •(g) Other, among hematological malignancies, the disease which is approved as an indication of allo-HSCT in our conference
排除标准
- •1) Major organ dysfunction
- •a) Total bilirubin: >= 2.0 mg/dl
- •b) Serum creatinine: >= 2.0 mg/dl
- •c) Left ventricular ejection fraction: < 50%
- •d) Pulmonary function test: %VC <40%, FEV1.0% <50% or SaO2 <90% on room air
- •e) AST or ALT >= 3 x UNL
- •2) Uncontrolled active infection
- •3) Uncontrolled CNS invasion
- •4) Poorly controlled insulin-treated diabetes mellitus
- •5) Poorly controlled hypertension
- •6) Patients with a severe complication including heart failure, coronary failure, acute myocardial infarction within the last three months, liver cirrhosis and uncontrolled interstitial pneumonia
- •7) Pregnant, lactating woman or woman of childbearing potential
- •8) Patients with a severe mental disorder who are likely to be unable to participate in the study
- •9) A history of hypersensitivity or allergy to any drugs in the conditioning regimen of this transplant
- •10) HIV antibody positivity
- •11) A history of administration of mogamulizumab
- •12) The physician in charge determines that there is no indication to perform this intervention
- •(Note: HBs antigen positivity and HCV antibody positivity is not exclusion criterion.The positivity of donor-specific antigen (DSA) is not excluded but DSA with MFI >=5000 should be avoided as much as possible)
研究者
相似试验
进行中（未招募）
1 期
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD ProphylaxisMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Acute Myeloid LeukemiaEUCTR2017-002331-41-DEniversity Medical Center Hamburg - Eppendorf440
尚未招募
2 期
Matched Unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with Acute Leukemia with identical GVHD prophylaxis - A randomized porspective European trial.high risk MDS10024324Acute leukemiaNL-OMON52639niversity Medical Center Hamburg-Eppendorf15
进行中（未招募）
1 期
Study to evaluate the impact of donor-specific antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study populatioRenal TransplantationMedDRA version: 18.1Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 100000004865EUCTR2013-004956-39-DEKlinikum der Universität München
已完成
1 期
HLA haploidentical stem cell transplantation using myeloablative regimen including ATGhematologic malignanciesJPRN-UMIN000004904Hyogo College of Medicine20
招募中
2 期
HLA-haploidentical stem cell transplantation using a low dose ATG and steroidJPRN-UMIN000028845Hyogo College of Medicine100